A Safety and Tolerability Clinical Trial of PST-611 in Dry Age-related Macular Degeneration

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions

Dry Age Related Macular Degeneration

Interventions

BIOLOGICAL

PST-611

PST-611 is a naked plasmid DNA encoding human transferrin administered into the ciliary muscle

Trial Locations (2)

CHU de Grenoble-Hôpital Michallon, Grenoble

Hôpital Cochin, Paris